DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.13 – $1.37
Volume33,166
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$12.98M
Price / earnings
0×
Price / book
0.18×
Price / sales
0.61×
EV / sales
0.77×
EV / EBITDA
-0.58×
Profitability
Earnings per share
$727.91
Return on assets
7,307.51%
Return on equity
11,528.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.44×
Current ratio
4.2×
Quick ratio
3.81×
Cash ratio
3.04×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DRIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5.31M
$5.18M
$5.58M
$5.23M
$5.01M
$5.37M
$6.75M
$7.6M
Cost of revenue
$2.17M
$1.99M
$2.38M
$2.43M
$1.99M
$2.41M
$2.87M
$3.4M
Gross profit
$3.15M
$3.19M
$3.2M
$2.8M
$3.02M
$2.96M
$3.88M
$4.2M
Selling, general and administrative
$8.9M
$7.57M
$8.12M
$8.73M
$9.17M
$8.44M
$9.18M
$10.59M
Research and development
$2.3M
$2.1M
$2.39M
$2.63M
$3.33M
$3.72M
$4.11M
$5.28M
Total operating expenses
$11.19M
$9.67M
$10.51M
$11.37M
$12.5M
$12.16M
$13.29M
$15.87M
Operating income
-$8.05M
-$6.48M
-$7.31M
-$8.56M
-$9.48M
-$9.2M
-$9.41M
-$11.67M
Interest expense
-$1.09M
-$1.12M
-$1.15M
-$1.1M
-$1.16M
$0
$0
$0
Income before taxes
-$8.87M
-$7.6M
-$8.19M
-$8.95M
-$10.47M
-$12.99M
-$9.21M
-$9.48M
Income taxes
-$18K
$328K
$57K
$83K
$0
$0
$22K
$155K
Net income
-$8.85M
-$7.92M
-$8.25M
-$9.03M
-$10.47M
-$12.99M
-$9.23M
-$9.63M
Net income attributable to common shareholders
-$8.85M
-$7.92M
$8.25B
-$16.11M
-$9.28M
-$8.78M
$6.79B
-$9.79M
EBITDA
-$7.52M
-$5.96M
-$6.79M
-$8.03M
-$8.94M
-$8.4M
-$8.15M
-$9.53M
Basic earnings per share
-$0.73
-$0.85
$1.25
—
-$2.96
-$3.54
$2.87
—
Diluted earnings per share
-$0.73
-$0.85
$1.25
—
-$2.96
-$3.54
$2.87
—
Recent news
Company coverage with links to the original publishers.
DarioHealth Corp. (DRIO) reported a quarterly loss of $0.44 per share, beating consensus estimates of $0.51 loss, with a 13.73% earnings surprise. Revenues reached $5.31 million, slightly exceeding expectations. However, the stock has plummeted 81.3% year-to-date compared to the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Globus Medical reported Q3 2026 earnings of $1.23 per share, beating consensus estimates of $1.20, but revenues of $763.72 million missed expectations by 3.69%. The company maintains a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. The Medical-Instruments industry ranks in the top 43% of Zacks industries.
DarioHealth (NASDAQ: DRIO) reported Q1 2026 results with second consecutive quarter of sequential revenue growth to $5.6 million, though down year-over-year due to non-recurrence of pharmaceutical customer revenue. The company achieved 21% year-over-year operating expense reduction and improved operating loss by 22% YoY. Channel partnerships now provide access to 116+ million covered lives, with potential expansion to 175+ million. The company maintains $20 million in cash and continues focus on subscription-based recurring revenue and AI-driven engagement programs.
DarioHealth Corp. (NASDAQ: DRIO), a digital health company specializing in chronic condition management, announced it will release its Q1 2026 financial results on May 13, 2026 at 8:30 a.m. ET. The company will host a conference call and webcast with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda to discuss results.
A study published in JMIR by Sanofi and Symphony Health revealed that DarioHealth's digital diabetes intervention platform can reduce healthcare costs by an estimated $5,077 per user annually, with 23% lower hospitalization rates and 26% lower all-cause medical charges.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.